A Phase 1, Randomized, Double-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study of PPI-1011 in Subjects to Assess Safety, Tolerability, and Pharmacokinetics
Latest Information Update: 03 Aug 2023
At a glance
- Drugs PPI-1011 (Primary)
- Indications Rhizomelic chondrodysplasia punctata
- Focus Adverse reactions; First in man
- Sponsors Med-Life Discoveries
Most Recent Events
- 03 Aug 2023 New trial record